Condition: COVID-19 · Immunodeficiency · Sponsor: Calmy Alexandra
The overall purpose of the trial is to evaluate the efficacy and safety of possible combination antiviral therapy direct antiviral agents (remdesivir + nirmatrelvir/r) versus the reference monotherapy (nirmatrelvir/r alone) and to assess the efficacy and safety of increasing the nirmatrelvir/r course from 5- to 10 days in immunocompromised patients diagnosed with asymptomatic or mild to moderate Coronavirus Disease 2019 (COVID-19).
This description comes directly from the study's public registry record.
Alexandra Calmy, MD PhD · +41 22 372 98 12 · alexandra.calmy@hug.ch
Chiara Fedeli, PhD · +41 (0)22 372 9817 · chiara.fedeli@hug.ch
Always discuss trial participation with your own doctor first.
| Basel University Hospital | Basel, Basel, Switzerland | Recruiting |
| Hôpitaux Universitaires de Genève | Geneva, Canton of Geneva, Switzerland | Recruiting |
| CHUV | Lausanne, Canton of Vaud, Switzerland | Recruiting |
| University Hospital Zurich | Zurich, Canton of Zurich, Switzerland | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07406217